Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton’s tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, ...
ASP2215 is well tolerated in doses of up to 300 mg per day in patients with relapsed or refractory A Researchers sought to determine whether KTE-X19, a CAR-T cell therapy, would be effective in ...
Kite Pharma, Inc. KITE announced that it has initiated a phase I/II study (ZUMA-4) on its lead pipeline candidate, KTE-C19, for the treatment of pediatric and young adults suffering from relapsed or ...
BEAVERTON, Ore., Sept. 16, 2021 /PRNewswire/ -- Tektronix, Inc., a leading worldwide provider of test and measurement solutions, today released KTE V7.1 software for the Keithley S530 Series ...
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc. (Nasdaq:KITE) presented updates on its advancing pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates and ...
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts After a median follow-up of ...
Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study. This is an ASCO Meeting Abstract from the 2021 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results